Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS
NCT03718247 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45
Last updated 2022-05-18
Summary
The purpose of this study is to evaluate the benefits of a low-carbohydrate, high-fat diet (ketogenic diet) in up to 50 subjects with relapsing-remitting multiple sclerosis (RRMS), a chronic neuro-inflammatory disease. The primary aim of this study is to provide evidence of tolerability of the ketogenic diet in patients with RRMS. The principal investigator hypothesizes that the diet may prove beneficial for participants disease state in multiple potential ways.The study consists of 5 visits over a 12 month period. During these visits subjects will undergo fasting lab work, micro-biome sampling, neurological testing, body composition analysis, meeting with dietitian, and will be asked to complete surveys as well as a diet recall log.
Conditions
- Relapsing Remitting Multiple Sclerosis
Interventions
- OTHER
-
Modified Atkins diet
High fat low carbohydrate diet.
Sponsors & Collaborators
-
University of Virginia
lead OTHER
Eligibility
- Min Age
- 12 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-10-31
- Primary Completion
- 2021-06-21
- Completion
- 2021-07-01
Countries
- United States
Study Locations
More Related Trials
-
Time Restricted Eating Outcomes in Multiple Sclerosis
NCT04389970 ·Status: COMPLETED ·Phase: NA
-
Functional Outcomes From Diets in Multiple Sclerosis
NCT05327322 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis
NCT05078177 ·Status: UNKNOWN ·Phase: PHASE1
-
A Specialized Diet for Multiple Sclerosis
NCT07033975 ·Status: RECRUITING ·Phase: NA
-
Examining the Impact of an Online, Non-restrictive Diet Among Persons With Multiple Sclerosis
NCT05712408 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Diet on Quality of Life in Multiple Sclerosis
NCT05007483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)
NCT06515782 ·Status: RECRUITING ·Phase: NA
-
Ketamine for MS Fatigue
NCT06064162 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis
NCT01848327 ·Status: COMPLETED ·Phase: NA
-
Calorie Restriction in Multiple Sclerosis
NCT04042415 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
NCT02746744 ·Status: COMPLETED ·Phase: PHASE3
-
Calorie Restriction in Multiple Sclerosis Patients
NCT02411838 ·Status: COMPLETED ·Phase: NA
-
Pilot and Feasibility Trial of a Telehealth Dietary Intervention for MS
NCT03372187 ·Status: COMPLETED ·Phase: NA
-
HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)
NCT04574024 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of Ocrevus in Relapsing Multiple Sclerosis
NCT04387734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Clinical Importance of Glucose Regulation in Relapsing MS
NCT03004079 ·Status: UNKNOWN
-
A run-in Study on the Safety and Tolerability of a Fasting Mimicking Diet in Relapsing Remitting Multiple Sclerosis
NCT06039007 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Low Fat Diet and Multiple Sclerosis
NCT00852722 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis
NCT03740295 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis
NCT03172741 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
NCT01719159 ·Status: COMPLETED ·Phase: PHASE2
-
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
NCT02398461 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
NCT03315923 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
NCT01601119 ·Status: COMPLETED
-
Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis
NCT02308670 ·Status: COMPLETED